CURRENT APPROACHES TO PREVENTING OVARIAN HYPERSTIMULATION SYNDROME


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Ovarian hyperstimulation syndrome (OHSS) is a complication of ovarian stimulation in the programs aimed to achieve pregnancy: in anovulation for natural conception, during intrauterine insemination, and in IVF programs. The authors of this paper attempted to summarize the data available in the literature and the results of their investigations pertaining to the development of severe OHSS, by modifying the tactics for management of an induced cycle.

Full Text

Restricted Access

About the authors

T. A NAZARENKO

Moscow Regional Research Institute of Obstetrics and Gynecology

Email: t.nazarenko@mail.ru

K. V KRASNOPOLSKAYA

Moscow Regional Research Institute of Obstetrics and Gynecology

Email: biooptima@gmail.com

References

  1. Клинические рекомендации РАРЧ: синдром гиперстимуляции яичников. М.; 2013.
  2. Lyons C.A., Wheeler C.A., Frishman G.N., Hackett R.J., Seifer D.B., Haning R.V. Jr. Early and late presentation of the ovarian hyperstimulation syndrome: two distinct entities with different risk factors. Hum. Reprod. 1994; 9(5): 792-9.
  3. Mathur R.S., Akande A.V., Keay S.D., Hunt L.P., Jenkins J.M. Distinction between early and late ovarian hyperstimulation syndrome. Fertil. Steril. 2000; 73(5): 901-7.
  4. Humaidan P., Quartarolo J., Papanikolaou E.G. Preventing ovarian hyperstimulation syndrome: guidance for the clinician. Fertil. Steril. 2010; 94(2): 389-400.
  5. Delvigne A., Rozenberg S. Preventive attitude ofphysicians to avoid OHSS in IVF patients. Hum. Reprod. 2001; 16(12): 2491-5.
  6. Golan A., Ronel R., Herman A., Soffer Y., Weinraub Z., Caspi E. Ovarian hyperstimulation syndrome: an update review. Obstet. Gynecol. Surv. 1989; 44(6): 430-40.
  7. Schenker J.G. Ovarian hyperstimulation syndrome. In: Wallach E., Zacur H., eds. Reproductive medicine and surgery. St. Louis: Mosby; 1995: 649-79.
  8. Navot D., Bergh P.A., Laufer N. Ovarian hyperstimulation syndrome in novel reproductive technologies: prevention and treatment. Fertil. Steril. 1992; 58(2): 249-61.
  9. Brinsden P.R, Wada I., Tan S.L., Balen A., Jacobs H.S. Diagnosis, prevention and management of ovarian hyperstimulation syndrome. Br. J. Obstet. Gynaecol. 1995; 102(10): 767-72.
  10. Zhu W.J., Li X.M., Chen X.M., Zhang L. Follicular aspiration during the selection phase prevents severe ovarian hyperstimulation in patients with polycystic ovary syndrome who are undergoing in vitro fertilization. Eur. J. Obstet. Gynecol. Reprod. Biol. 2005; 122(1): 79-84.
  11. Aflatoonian A., Mahani I.M., Tabibnejad N., Aflatoonian B., Aflatoonian R. Comparison of coasting with aspiration half of follicles before hCG injection for prevention of OHSS in ART cycles. Hum. Reprod. 2006; 21(Suppl.1): i37.
  12. Moreno L., Diaz I., Pacheco A., Zuniga A., Requena A., Garcia-Velasco J.A. Extended coasting duration exerts a negative impact on IVF cycle outcome due to premature luteinization. Reprod. Biomed. Online. 2004; 9(5): 500-4.
  13. Аншина М.Б. ЭКО в естественных циклах (клиническая лекция). Проблемы репродукции. 2008; 3: 48-52.
  14. Nargund G., Hutchison L., Scaramuzzi R., Campbell S. Low-dose HCG is useful in preventing OHSS in high-risk women without adversely affecting the outcome of IVF cycles. Reprod. Biomed. Online. 2007; 14(6): 682-5.
  15. Youssef M.A., van Wely M., Hassan M.A., Al-Inany H.G., Mochtar M., Khattab S., van der Veen F. Can dopamine agonists reduce the incidence and severity of OHSS in IVF/ICSI treatment cycles? A systematic review and meta-analysis. Hum. Reprod. Update. 2010; 16(5): 459-66.
  16. Alvarez C., Martf-Bonmatf L., Novella-Maestre E., Sanz R., Gomez R., Fernandez-Sanchez M. et al. Dopamine agonist caber-goline reduces hemoconcentration and ascites in hyperstimulated women undergoing assisted reproduction. J. Clin. Endocrinol. Metab. 2007; 92(8): 2931-7.
  17. Ndukwe G., Thornton S., Fishel S., Dowell K., Aloum M. Severe ovarian hyperstimulation syndrome: is it really preventable by prophylactic intravenous albumin? Fertil. Steril. 1997; 68(5): 851-4.
  18. Ben-Chetrit A., Eldar-Geva T., Gal M., Huerta M., Mimon T., Algur N. et al. The questionable use of albumin for the prevention of ovarian hyperstimulation syndrome in an IVF programme: a randomized placebo-controlled trial. Hum. Reprod. 2001; 16(9): 1880-4.
  19. Gokmen O., Ugur M., Ekin M., Keles G., Turan C., Oral H. Intravenous albumin versus hydroxyethyl starch for the prevention of ovarian hyperstimulation in an in-vitro fertilization programme: a prospective randomized placebo controlled study. Eur. J. Obstet. Gynecol. Reprod. Biol. 2001; 96(2): 187-92.
  20. Youssef M.A., Al-Inany H.G., Evers J.L., Aboulghar M. Intravenous fluids for prevention of severe ovarian hyperstimulation syndrome. Cochrane Database Syst. Rev. 2011; (2): CD001302.
  21. Kolibianakis E.M., Zikopoulos K., Schiettecatte J., Smitz J., Tournaye H., Camus M. et al. Profound LH suppression after GnRH antagonist administration is associated with a significantly higher ongoing pregnancy rate in IVF. Hum. Reprod. 2004; 19(11): 2490-6.
  22. Pelinck M.J., Vogel N.E., Hoek A., Arts E.G., Simons A.H., Heineman M.J. Minimal stimulation IVF with late follicular phase administration of the GnRH antagonist cetrorelix and concomitant substitution with recombinant FSH: a pilot study. Hum. Reprod. 2005; 20(3): 642-8.
  23. Al-Inany H., Aboulghar M., Mansour R., Serour G. Meta-analysis of recombinant versus urinary-derived FSH: an update. Hum Reprod. 2003; 18(2): 305-13.
  24. Daya S., Gunby J. Recombinant versus urinary follicle stimulating hormone for ovarian stimulation in assisted reproduction cycles. Cochrane Database Syst. Rev. 2000; (4): CD002810.
  25. Christin-Maitre S., Hugues J.N. Recombinant FSH Study Group. A comparative randomized multicentric study comparing the step-up versus step-down protocol in polycystic ovary syndrome. Hum. Reprod. 2003; 18(8): 1626-31.
  26. Leader A. Monofollicular Ovulation Induction Study Group. Improved monofollicular ovulation in anovulatory or oligoovulatory women after a low-dose step-up protocol with weekly increments of 25 international units of follicle-stimulating hormone. Fertil. Steril. 2006; 85(6): 1766-73.
  27. Engmann L., DiLuigi A., Schmidt D., Nulsen J., Maier D., Benadiva C. The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study. Fertil. Steril. 2008; 89(1): 84-91.
  28. Баркалина Н.В., Корнеева И.Е. Агонисты гонадотропин-релизинг гормона в программах вспомогательных репродуктивных технологий (обзор литературы). Проблемы репродукции. 2010; 4: 54-9.
  29. Kolibianakis E.M., Schultze-Mosgau A., Schroer A., van Steirteghem A., Devroey P., Diedrich K., Griesinger G. A lower ongoing pregnancy rate can be expected when GnRH agonist is used for triggering final oocyte maturation instead of HCG in patients undergoing IVF with GnRH antagonists. Hum Reprod. 2005; 20(10): 2887-92.
  30. Humaidan P., Ejdrup Bredkjaer H., Westergaard L.G., Yding Andersen C. 1,500 IU human chorionic gonadotropin administered at oocyte retrieval rescues the luteal phase when gonadotropin-releasing hormone agonist is used for ovulation induction: a prospective, randomized, controlled study. Fertil. Steril. 2010; 93(3): 847-5.
  31. Castillo J.C., Dolz M., Bienvenido E., Abad L., Casan E.M., Bonilla-Musoles F. Cycles triggered with GnRH agonist: exploring low-dose HCG for luteal support. Reprod. Biomed. Online. 2010; 20(2): 175-81.
  32. Griesinger G., Kolibianakis E.M., Papanikolaou E.G., Diedrich K., Van Steirteghem A., Devroey P. et al. Triggering of final oocyte maturation with gonadotropin-releasing hormone agonist or human chorionic gonadotropin. Live birth after frozen-thawed embryo replacement cycles. Fertil. Steril. 2007; 88(3): 616-21.
  33. Wada I., Matson P.L., Troup S.A., Hughes S., Buck P., Lieberman B.A. Outcome of treatment subsequent to the elective cryopreservation of all embryos from women at risk of the ovarian hyperstimulation syndrome. Hum. Reprod. 1992; 7(7): 962-6.
  34. Queenan J.T.Jr., Veeck L.L., Toner J.P, OehningerS., Muasher S.J. Cryopreservation of all prezygotes in patients at risk of severe hyperstimulation does not eliminate the syndrome, but the chances of pregnancy are excellent with subsequent frozen-thaw transfers. Hum. Reprod. 1997; 12(7): 1573-6.
  35. D’Angelo A., Amso N.N. Embryo freezing for preventing ovarian hyperstimulation syndrome: a Cochrane review. Hum. Reprod. 2002; 17(11): 2787-94.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2013 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies